Digital Therapeutics at a Crossroads: Why CMS Coverage Alone Won’t Drive Adoption 

Elina Sabilova, Billing specialist, WCH 

The digital therapeutics industry entered 2025 with cautious optimism following CMS’s introduction of dedicated reimbursement codes, but early adoption patterns suggest the path to mainstream integration remains challenging. Despite new coverage pathways taking effect January 1, 2025, initial implementation reveals a complex landscape where reimbursement availability doesn’t automatically translate to provider adoption or patient access. 

The contrast between industry projections and current reality is stark. Market forecasts show growth to $32.5 billion by 2030. Yet, Pear Therapeutics’ bankruptcy in April 2023 – despite being the first company to secure FDA clearance for prescription digital therapeutics – highlighted fundamental business model challenges that persist industry-wide. The company’s assets sold for just $6 million at auction, down from its $1.6 billion SPAC valuation two years earlier. 

CMS Reimbursement Reality: Early Implementation Challenges 

CMS established new coverage pathways for digital mental health treatments effective January 1, 2025, creating dedicated reimbursement mechanisms for the first time. The new framework includes codes for device supply, initial patient education, and ongoing treatment management, with estimated reimbursement rates ranging from $19 to $ 20 per treatment session. 

However, early implementation reveals limited provider uptake in the first half of 2025. Healthcare systems report challenges with contractor pricing variations, where identical digital therapeutic interventions receive different coverage determinations and payment rates depending on geographic region and the responsible Medicare Administrative Contractor (MAC), creating significant uncertainty for revenue planning and workflow investments. 

According to coverage policies reviewed by industry analysts as of mid-2025, major insurers maintain restrictive approaches. Coverage reviews suggest limited DTx formulary inclusion, with most plans requiring extensive prior authorization processes and demonstrated traditional therapy failures before approving digital interventions. 

What Pear’s Failure Teaches About Business Models 

Pear Therapeutics’ bankruptcy offers concrete lessons about DTx commercialization challenges. Despite FDA approvals for reSET (substance use disorder), reSET-O (opioid use disorder), and Somryst (chronic insomnia), the company struggled with three critical issues: 

Reimbursement gaps: Even with FDA approval, most insurers required extensive prior authorization processes. Pear spent months negotiating coverage decisions, often resulting in partial coverage or high patient copays that deterred usage. 

Provider workflow integration: Clinicians reported difficulty incorporating DTx monitoring into existing patient care workflows. Unlike traditional medications with clear dosing protocols, DTx required ongoing patient engagement, tracking, and data interpretation that didn’t fit standard 15-minute appointment models. 

Patient adherence challenges: Real-world engagement rates fell significantly below clinical trial levels. While Pear’s products showed efficacy in controlled settings, maintaining patient engagement over 12-16 week treatment courses proved difficult without dedicated support staff. 

The company’s competitor, DynamiCare Health, analyzed Pear’s failure in a LinkedIn post by CEO Eric Gastfriend, attributing it partly to targeting difficult-to-treat conditions with high-priced solutions, rather than focusing on more common, easier-to-manage conditions where DTx could demonstrate clear value propositions. 

Provider Adoption: Beyond Reimbursement Barriers 

Healthcare provider adoption challenges extend beyond financial considerations, reflecting complex implementation science questions about workflow integration, staff training, and organizational change management. Provider surveys and health system reports reveal multiple barriers: 

Staff training requirements: Implementing DTx requires training clinical staff on device onboarding, patient monitoring protocols, and data interpretation. Healthcare systems report significant training investments, with estimates ranging from 4-6 hours of initial provider training plus ongoing support infrastructure. 

Technology integration gaps: Most DTx platforms don’t integrate seamlessly with major EHR systems. Providers report manually entering DTx-generated data or maintaining separate tracking systems, adding administrative burden without clear efficiency gains. 

Patient selection complexity: Identifying appropriate DTx candidates requires understanding patient technology literacy, motivation levels, and social support systems. Providers lack standardized assessment tools for these factors, leading to inconsistent patient selection and variable outcomes. 

Major health systems are experimenting with different implementation models. Intermountain Health piloted NeuroFlow’s behavioral health platform in five primary care locations in Colorado, focusing on integrating technology into Epic EHR and standardizing behavioral healthcare measurement. Cleveland Clinic has collaborated with Ayble Health on digital health platforms for chronic gastrointestinal conditions, allowing patients to access content co-developed with the Clinic. 

However, these pilot programs reveal mixed results. While patient engagement and satisfaction metrics often show positive trends, demonstrating clear clinical outcome improvements compared to standard care remains challenging, raising questions about cost-effectiveness given workflow complexity. 

Technology Evolution: AI Integration and Next-Generation Capabilities 

The DTx sector is experiencing rapid technological advancement through artificial intelligence and machine learning integration. Next-generation platforms incorporate predictive analytics capabilities that adapt intervention protocols based on individual patient response patterns. These AI-enhanced systems move beyond static therapeutic content delivery toward dynamic, personalized treatment optimization. 

Virtual reality (VR) and augmented reality (AR) integration represents another significant development trajectory. VR-based DTx applications for pain management, phobia treatment, and rehabilitation demonstrate particular promise, offering immersive therapeutic environments that may enhance traditional cognitive behavioral therapy approaches. 

Interoperability improvements are enabling DTx integration with electronic health record (EHR) systems and healthcare information exchanges. These developments address provider workflow concerns by incorporating DTx-generated data into existing clinical documentation and decision-support systems. 

Market Segmentation: Prescription vs. Consumer-Directed Models 

The DTx market operates through two distinct channels with different value propositions and business models. Prescription DTx applications targeting serious medical conditions require FDA clearance, clinical evidence demonstration, and a healthcare provider prescription. These applications typically address specific disease states with measurable clinical outcomes and established treatment protocols. 

Consumer-directed DTx applications focus on wellness, prevention, and health behavior modification without explicit regulatory requirements. These platforms often generate revenue through direct-pay subscriptions or employer wellness program partnerships, avoiding reimbursement complexity while accepting limited clinical validation requirements. 

The prescription model offers greater clinical credibility and potential reimbursement coverage but requires significant regulatory investment and longer market entry timelines. Consumer-directed approaches enable faster market entry and simpler business models but face challenges in demonstrating clinical value and achieving sustainable engagement rates. 

Economic Impact Analysis: Value-Based Care Alignment 

DTx solutions demonstrate particular value within value-based care contracts, where outcome improvements and cost reductions directly benefit healthcare organizations. Early evidence suggests DTx interventions may reduce hospitalization rates, emergency department utilization, and specialist referrals for specific condition categories. 

Mental health DTx applications show promise in addressing provider shortage challenges, particularly in rural and underserved areas. By extending therapeutic capacity through digital platforms, these solutions may improve access while reducing per-episode treatment costs. However, long-term economic impact data remains limited, creating challenges for value-based contract negotiations. 

Population health management represents another economic opportunity, where DTx platforms enable proactive intervention for at-risk patient populations. These applications may identify deteriorating conditions before acute episodes occur, potentially preventing costly hospitalizations and emergency interventions. 

Industry Consolidation and Platform Integration 

The DTx industry is likely to experience consolidation as successful companies expand their therapeutic area coverage and unsuccessful ventures exit the market. Platform consolidation may emerge, where comprehensive DTx suites address multiple conditions within unified technology frameworks rather than condition-specific point solutions. 

Integration with established healthcare technology vendors represents another likely development. EHR companies, telehealth platforms, and remote monitoring providers may acquire DTx capabilities to offer comprehensive digital health solutions within existing provider relationships. 

Regulatory evolution will continue shaping market dynamics, with potential expansion of CMS coverage to additional therapeutic areas and development of outcomes-based reimbursement models. International regulatory harmonization may also emerge as DTx companies seek global market access through standardized approval processes. 

Realistic Expectations for DTx Growth 

Digital therapeutics face a more nuanced adoption pathway than early industry projections suggested. CMS reimbursement pathways provide necessary infrastructure, but successful integration requires addressing workflow challenges, demonstrating clear clinical value, and developing sustainable business models that account for real-world implementation complexities. 

The industry’s next phase will likely favor companies that can demonstrate measurable outcomes improvement, seamless workflow integration, and cost-effective implementation models. Providers considering DTx adoption should focus on solutions with proven real-world effectiveness data, clear staff training protocols, and sustainable reimbursement pathways rather than relying solely on FDA approval status or projected market growth figures. 

Success in DTx will ultimately depend less on regulatory milestones and more on solving practical healthcare delivery challenges through effective implementation science approaches while demonstrating clear value to patients, providers, and payers. 

Sources 

1. “Is Digital Therapeutics Finally Having Its Moment?” Healthcare IT News, August 1, 2025. 

2. “Digital Therapeutics Market Size | Industry Report, 2030.” Grand View Research, 2025. 

3. “Digital Therapeutics Market Size, Share | Industry Report – 2032.” SkyQuest Technology Consulting, 2025. 

4. “Medicare Implements Digital Mental Health Treatment Codes.” AAPC Knowledge Center, August 2025. 

5. “CMS Issues Key Medicare Payment Policy Final Rules for Calendar Year 2025.” Sidley Austin LLP, November 7, 2024. 

6. “Now that digital therapeutics have Medicare coverage, the real test begins.” Healthcare Brew, April 4, 2025. 

7. “CMS makes changes to behavioral health, new codes, and cuts to rates in 2025 MPFS final rule.” NAHRI, November 2024. 

8. “What CMS’s proposed reimbursement codes could mean for the digital therapeutics industry.” Healthcare Brew, July 22, 2024. 

9. “CMS puts forward meager offering for digital health in final Medicare physician fee schedule rule.” Fierce Healthcare, November 5, 2024. 

10. “US Healthcare Reimbursement 2025.” IDR Medical, June 18, 2025. 

11. “The fall and rise of digital therapeutics.” Pharmaphorum, 2024. 

12. “What Intermountain Health Hopes to Achieve with its New Behavioral Health Partnership.” MedCity News, July 18, 2024. 

13. “Ayble Health, Cleveland Clinic collab to bring virtual behavioral health, nutrition counseling to GI patients.” Fierce Healthcare, October 31, 2024. 

14. “Implementing digital therapeutics – Kaiser Permanente’s perspective.” Healthcare IT News, June 13, 2024. 

15. “Pear Therapeutics Bankruptcy: A Competitor’s Perspective.” LinkedIn, Eric Gastfriend, April 10, 2023.